IMPORTANT DEADLINE REMINDER: The Schall Law Firm Encourages Investors in Eagle Pharmaceuticals, Inc. with Losses to Contact the FirmAccesswire • 12/29/23
INVESTOR ACTION ALERT: The Schall Law Firm Encourages Investors in Eagle Pharmaceuticals, Inc. with Losses to Contact the FirmAccesswire • 12/27/23
Robbins LLP Reminds Investors of Eagle Pharmaceuticals, Inc. that There is Still Time to Move for Lead Plaintiff in the EGRX Class ActionBusiness Wire • 12/27/23
FINAL DEADLINE APPROACHING: The Schall Law Firm Encourages Investors in Eagle Pharmaceuticals, Inc. with Losses to Contact the FirmAccesswire • 12/22/23
INVESTOR ACTION NOTICE: The Schall Law Firm Encourages Investors in Eagle Pharmaceuticals, Inc. with Losses to Contact the FirmAccesswire • 12/19/23
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Eagle Pharmaceuticals, Inc. - EGRXPRNewsWire • 12/19/23
Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Eagle Pharmaceuticals, Inc. (EGRX)Business Wire • 12/14/23
Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of Eagle Pharmaceuticals, Inc. (EGRX) InvestorsBusiness Wire • 12/13/23
Eagle Pharmaceuticals, Inc. (EGRX) Investor Notice: Robbins LLP Reminds Investors of Class Action Filed Against Eagle Pharmaceuticals, Inc.Business Wire • 12/13/23
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Eagle Pharmaceuticals, Inc. (EGRX)Business Wire • 12/13/23
EAGLE PHARMACEUTICALS ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Eagle Pharmaceuticals, Inc. and Encourages Investors to Contact the FirmBusiness Wire • 12/13/23
INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Eagle Pharmaceuticals, Inc. (EGRX) InvestorsBusiness Wire • 12/12/23
EGRX CLASS ACTION NOTICE: Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit Against Eagle Pharmaceuticals, Inc.Business Wire • 12/11/23
INVESTIGATION ALERT: Berger Montague is Investigating Securities Fraud Claims on Behalf of Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX) InvestorsPRNewsWire • 12/07/23
Eagle Pharmaceuticals to Present Abstract on Post-hoc Analysis of Amisulpride at the 77th PGA (PostGraduate Assembly in Anesthesiology) in New York CityGlobeNewsWire • 12/06/23
ROSEN, LEADING INVESTOR COUNSEL, Encourages Eagle Pharmaceuticals, Inc. Investors to Inquire About Securities Class Action Investigation - EGRXPRNewsWire • 12/04/23
EAGLE PHARMACEUTICALS ALERT: Bragar Eagel & Squire, P.C. is Investigating Eagle Pharmaceuticals, Inc. on Behalf of Eagle Pharmaceuticals Stockholders and Encourages Investors to Contact the FirmBusiness Wire • 12/02/23
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Eagle Pharmaceuticals, Inc. (EGRX) on Behalf of InvestorsBusiness Wire • 11/30/23
Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Eagle Pharmaceuticals, Inc. (EGRX)Business Wire • 11/30/23
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Eagle Pharmaceuticals, Inc. (EGRX) on Behalf of InvestorsBusiness Wire • 11/30/23
ROSEN, A TOP RANKED LAW FIRM, Encourages Eagle Pharmaceuticals, Inc. Investors to Inquire About Securities Class Action Investigation – EGRXBusiness Wire • 11/30/23
The Law Offices of Frank R. Cruz Announces Investigation of Eagle Pharmaceuticals, Inc. (EGRX) on Behalf of InvestorsBusiness Wire • 11/29/23
Eagle Pharmaceuticals Announces Receipt of Notification of Deficiency from Nasdaq Regarding Requirement to Timely File Quarterly Report on Form 10-QGlobeNewsWire • 11/29/23
Down -33.75% in 4 Weeks, Here's Why Eagle Pharmaceuticals (EGRX) Looks Ripe for a TurnaroundZacks Investment Research • 11/27/23
